Ultima-Dianabol 10 Mg 50 Tablets Ultima Pharma USA

Product Overview

Ultima Pharma USA’s Dianabol 10 mg presents methandienone, featuring C1,2 double bond modification conferring unique anabolic signaling with 17α-alkylation enabling oral bioavailability (~3-6 hour half-life), in small round scored tablets replicating early methandienone morphology for institutional catalog integration across DEA-registered platforms. The 50-tablet HDPE bottle configuration supports CIII-compliant inventory reconciliation mandated under 21 CFR 1304.22 requiring detailed Schedule III accountability for institutional handlers maintaining federal compliance.

U.S.-domiciled GMP manufacturing maintains molecular specifications (MW 300.44) distinguishing legitimate Schedule III pedigree from underground powder conversions exhibiting characteristic under-dosing. This prescription-equivalent presentation serves institutional buyers requiring Form 222 triplicate documentation across 50 U.S. jurisdictions eliminating international sourcing risks inherent to grey-market alternatives exposing end-users to customs seizure and authenticity uncertainty.

Ultima-Dianabol positions exclusively within verified DEA Schedule III ecosystems targeting licensed institutional clientele demonstrating controlled substance handling protocols under 21 CFR 1301.13 registrant requirements, maintaining strict commercial positioning devoid of therapeutic claims or performance guidance characteristic of legitimate CIII workflows.​

Brand & Manufacturer Information

Ultima Pharma USA manufactures DEA Schedule III controlled substances through domestic GMP facilities serving institutional performance networks requiring rigorous DEA registrant verification. Dianabol 10 mg anchors Ultima’s foundational oral anabolic catalog alongside Stan/Oxa maintaining dosage standardization (10 mg base) while authenticating supply chain legitimacy versus powder-pressed alternatives rejected by institutional handlers universally.

Domestic warehousing supports encrypted Form 222 platforms eliminating customs risk while serialized batch documentation verifies 10 mg potency distinguishing Ultima from non-pharmaceutical origins lacking controlled substance pedigree essential for institutional bulk procurement.​

Active Compound Information

Contains methandienone (17α-methyl-Δ¹-testosterone), first-generation anabolic steroid exhibiting C1,2 diene unsaturation conferring rapid protein synthesis stimulation characteristic of testosterone derivatives with 17α-methylation preventing first-pass metabolism. DEA Schedule III classification reflects hepatotoxicity profile, estrogenic aromatization potential, and glycogenolytic activity supporting performance applications beyond original medical indications discontinued post-FDA reevaluation.

10 mg strength replicates historical prescription methandienone (5-10 mg therapeutic range) while 50-tablet count supports institutional packaging. Molecular formula C20H28O2; WADA S1.1a prohibited globally with sensitive detection methodology.​

Product Specifications

Quality Control & Testing Standards

10 mg methandienone mandates USP <621> potency assay (HPLC 90-110%), USP <711> dissolution, USP <905> uniformity, and Δ¹-unsaturation verification confirming pharmaceutical-grade specifications. Ultima batch documentation verifies C20H28O2 identity distinguishing legitimate GMP production from underground conversions.

50-tablet CIII configuration incorporates USP <671> barriers preventing oxidative degradation while child-resistant closure satisfies 21 CFR 310.310(a). Domestic stability maintains ICH Q1A(R2) 36-month shelf-life exceeding underground alternatives.​

Intended Use & Market Positioning

Ultima-Dianabol 10 mg serves DEA-registered CIII institutional researchers managing foundational Schedule III anabolic inventories exclusively through encrypted fulfillment requiring Form 222 accountability. Prescription-equivalent positioning serves verified institutional clientele.

Zero protocols, cycles, or outcomes represented maintaining commercial CIII positioning.​

Legal & Regulatory Disclaimer

Methandienone constitutes DEA Schedule III under 21 USC §812; non-medical handling violates Controlled Substances Act (5 years/$250,000 penalties). Institutional buyers assume Form 222/DEA licensing liability; no medical claims provided.​